ZVRA: Q2 revenue up 53% to $39.7M, driven by MIPLYFFA growth and robust cash position of $260.2M
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA U.S. sales and expanding adoption across both adult and pediatric NPC patients. Cash reserves reached $260.2 million, supporting ongoing investments and pipeline progress, while the company advances EU regulatory efforts for arimoclomol.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue rose 53% year-over-year to $39.7 million, led by strong MIPLYFFA U.S. sales and expanding adoption across both adult and pediatric NPC patients. Cash reserves reached $260.2 million, supporting ongoing investments and pipeline progress, while the company advances EU regulatory efforts for arimoclomol.
Based on